MRNA Fundamental Analysis - MODERNA INC

Name: MODERNA INC (MRNA) Stock
Brand: MODERNA INC
Rating: 3 (3 reviews)

Fundamental Rating

MRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, MRNA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MRNA has reported negative net income.

MRNA had a negative operating cash flow in the past year.

In multiple years MRNA reported negative net income over the last 5 years.

In multiple years MRNA reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a decent Return On Assets value of -24.17%, MRNA is doing good in the industry, outperforming 72.50% of the companies in the same industry.

With a decent Return On Equity value of -30.89%, MRNA is doing good in the industry, outperforming 76.46% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.17%
ROE	-30.89%
ROIC	N/A

ROA(3y)-6.14%

ROA(5y)4.17%

ROE(3y)-7.66%

ROE(5y)6.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MRNA has a Gross Margin of 68.32%. This is amongst the best in the industry. MRNA outperforms 80.98% of its industry peers.

In the last couple of years the Gross Margin of MRNA has declined.

The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	68.32%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.55%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MRNA has been increased compared to 1 year ago.

MRNA has more shares outstanding than it did 5 years ago.

The debt/assets ratio for MRNA has been reduced compared to a year ago.

2.2 Solvency

MRNA has an Altman-Z score of 3.31. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.

MRNA has a Altman-Z score of 3.31. This is in the better half of the industry: MRNA outperforms 70.81% of its industry peers.

MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.00, MRNA perfoms like the industry average, outperforming 46.89% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.31

ROIC/WACCN/A

WACC8.69%

2.3 Liquidity

A Current Ratio of 3.93 indicates that MRNA has no problem at all paying its short term obligations.

MRNA has a Current ratio (3.93) which is comparable to the rest of the industry.

A Quick Ratio of 3.77 indicates that MRNA has no problem at all paying its short term obligations.

MRNA has a Quick ratio of 3.77. This is comparable to the rest of the industry: MRNA outperforms 47.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.93
Quick Ratio	3.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MRNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.66%.

The Revenue for MRNA has decreased by -52.75% in the past year. This is quite bad

Measured over the past years, MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.

EPS 1Y (TTM)-38.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1800%

Revenue 1Y (TTM)-52.75%

Revenue growth 3Y-44.04%

Revenue growth 5Y122.01%

Sales Q2Q%-45.44%

3.2 Future

The Earnings Per Share is expected to grow by 20.26% on average over the next years. This is a very strong growth

Based on estimates for the next years, MRNA will show a quite strong growth in Revenue. The Revenue will grow by 17.50% on average per year.

EPS Next Y-7.31%

EPS Next 2Y7.12%

EPS Next 3Y12.73%

EPS Next 5Y20.26%

Revenue Next Year-41%

Revenue Next 2Y-19.3%

Revenue Next 3Y-7.47%

Revenue Next 5Y17.5%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MRNA's earnings are expected to grow with 12.73% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y7.12%

EPS Next 3Y12.73%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MRNA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MODERNA INC

NASDAQ:MRNA (11/12/2025, 8:00:01 PM)

Premarket: 26.3 -0.41 (-1.54%)

26.71

+0.3 (+1.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06/bmo

Earnings (Next)02-12 2026-02-12/amc

Inst Owners74.95%

Inst Owner Change-1.17%

Ins Owners2.55%

Ins Owner Change0.02%

Market Cap10.43B

Revenue(TTM)3.24B

Net Income(TTM)-2.90B

Analysts55.33

Price Target43.12 (61.44%)

Short Float %17.95%

Short Ratio6.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)25.41%

Min EPS beat(2)21.22%

Max EPS beat(2)29.6%

EPS beat(4)3

Avg EPS beat(4)36.52%

Min EPS beat(4)-6.26%

Max EPS beat(4)101.54%

EPS beat(8)6

Avg EPS beat(8)-7.95%

EPS beat(12)8

Avg EPS beat(12)0.84%

EPS beat(16)11

Avg EPS beat(16)4.98%

Revenue beat(2)1

Avg Revenue beat(2)11.48%

Min Revenue beat(2)-0.3%

Max Revenue beat(2)23.26%

Revenue beat(4)3

Avg Revenue beat(4)17.36%

Min Revenue beat(4)-0.3%

Max Revenue beat(4)46.04%

Revenue beat(8)7

Avg Revenue beat(8)31.8%

Revenue beat(12)9

Avg Revenue beat(12)25.64%

Revenue beat(16)12

Avg Revenue beat(16)20.85%

PT rev (1m)-8.98%

PT rev (3m)-7.7%

EPS NQ rev (1m)-1.97%

EPS NQ rev (3m)-12%

EPS NY rev (1m)0.21%

EPS NY rev (3m)3.69%

Revenue NQ rev (1m)-2.17%

Revenue NQ rev (3m)-23.69%

Revenue NY rev (1m)-1.27%

Revenue NY rev (3m)-8.72%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.39
P/FCF	N/A
P/OCF	N/A
P/B	1.11
P/tB	1.12
EV/EBITDA	N/A

EPS(TTM)-8.07

EYN/A

EPS(NY)-7.91

Fwd EYN/A

FCF(TTM)-8.96

FCFYN/A

OCF(TTM)-6.91

OCFYN/A

SpS7.88

BVpS24.06

TBVpS23.81

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.17%
ROE	-30.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	68.32%
FCFM	N/A

ROA(3y)-6.14%

ROA(5y)4.17%

ROE(3y)-7.66%

ROE(5y)6.83%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.55%

GM growth 5YN/A

F-Score4

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	386.06%
Cap/Sales	26.09%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.93
Quick Ratio	3.77
Altman-Z	3.31

F-Score4

WACC8.69%

ROIC/WACCN/A

Cap/Depr(3y)261.63%

Cap/Depr(5y)224.68%

Cap/Sales(3y)14.96%

Cap/Sales(5y)10.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-38.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1800%

EPS Next Y-7.31%

EPS Next 2Y7.12%

EPS Next 3Y12.73%

EPS Next 5Y20.26%

Revenue 1Y (TTM)-52.75%

Revenue growth 3Y-44.04%

Revenue growth 5Y122.01%

Sales Q2Q%-45.44%

Revenue Next Year-41%

Revenue Next 2Y-19.3%

Revenue Next 3Y-7.47%

Revenue Next 5Y17.5%

EBIT growth 1Y35.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-0.33%

EBIT Next 3Y14.92%

EBIT Next 5Y18.99%

FCF growth 1Y-364.19%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1093.36%

OCF growth 3YN/A

OCF growth 5YN/A

MODERNA INC / MRNA FAQ

What is the fundamental rating for MRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRNA.

What is the valuation status of MODERNA INC (MRNA) stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (MRNA). This can be considered as Overvalued.

How profitable is MODERNA INC (MRNA) stock?

MODERNA INC (MRNA) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for MRNA stock?

The Earnings per Share (EPS) of MODERNA INC (MRNA) is expected to decline by -7.31% in the next year.

MODERNA INC (MRNA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MODERNA INC / MRNA FAQ

What is the fundamental rating for MRNA stock?

What is the valuation status of MODERNA INC (MRNA) stock?

How profitable is MODERNA INC (MRNA) stock?

Can you provide the expected EPS growth for MRNA stock?